Ezio Bonifacio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6560833/publications.pdf

Version: 2024-02-01

378 papers

24,949 citations

83 h-index 139 g-index

394 all docs

394 docs citations

times ranked

394

16506 citing authors

#	Article	IF	CITATIONS
1	Heterogeneity of DKA Incidence and Age-Specific Clinical Characteristics in Children Diagnosed With Type 1 Diabetes in the TEDDY Study. Diabetes Care, 2022, 45, 624-633.	8.6	7
2	Reproducibility of 10x Genomics single cell RNA sequencing method in the immune cell environment. Journal of Immunological Methods, 2022, 502, 113227.	1.4	3
3	Telomere length is not a main factor for the development of islet autoimmunity and type 1 diabetes in the TEDDY study. Scientific Reports, 2022, 12, 4516.	3. 3	6
4	Distinguishing activated T regulatory cell and TÂconventional cells by singleâ€cell technologies. Immunology, 2022, 166, 121-137.	4.4	4
5	Sources of dietary gluten in the first 2 years of life and associations with celiac disease autoimmunity and celiac disease in Swedish genetically predisposed children: The Environmental Determinants of Diabetes in the Young (TEDDY) study. American Journal of Clinical Nutrition, 2022, 116, 394-403.	4.7	5
6	Autoantibodies against <scp>ATP4A</scp> are a feature of the abundant autoimmunity that develops in firstâ€degree relatives of patients with type 1 diabetes. Pediatric Diabetes, 2022, 23, 714-720.	2.9	2
7	A classification and regression tree analysis identifies subgroups of childhood type 1 diabetes. EBioMedicine, 2022, 82, 104118.	6.1	21
8	Shortening the paths to type 1 diabetes mellitus prevention. Nature Reviews Endocrinology, 2021, 17, 73-74.	9.6	5
9	A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. Med, 2021, 2, 149-163.e4.	4.4	85
10	Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial. Diabetologia, 2021, 64, 1079-1092.	6.3	31
11	An Age-Related Exponential Decline in the Risk of Multiple Islet Autoantibody Seroconversion During Childhood. Diabetes Care, 2021, 44, 2260-2268.	8.6	23
12	The transCampus Metabolic Training Programme Explores the Link of SARS-CoV-2 Virus to Metabolic Disease. Hormone and Metabolic Research, 2021, 53, 204-206.	1.5	2
13	Transcriptional networks in at-risk individuals identify signatures of type 1 diabetes progression. Science Translational Medicine, 2021, 13, .	12.4	22
14	Associations of breastfeeding with childhood autoimmunity, allergies, and overweight: The Environmental Determinants of Diabetes in the Young (TEDDY) study. American Journal of Clinical Nutrition, 2021, 114, 134-142.	4.7	14
15	A public health antibody screening indicates a marked increase of SARS-CoV-2 exposure rate in children during the second wave. Med, 2021, 2, 571-572.	4.4	32
16	Multi-omics profiling of living human pancreatic islet donors reveals heterogeneous beta cell trajectories towards type 2 diabetes. Nature Metabolism, 2021, 3, 1017-1031.	11.9	76
17	Transient Depletion of Foxp3+ Regulatory T Cells Selectively Promotes Aggressive Î ² Cell Autoimmunity in Genetically Susceptible DEREG Mice. Frontiers in Immunology, 2021, 12, 720133.	4.8	7
18	Functional and metabolic fitness of human CD4 ⁺ T lymphocytes during metabolic stress. Life Science Alliance, 2021, 4, e202101013.	2.8	2

#	Article	IF	CITATIONS
19	100 Years of insulin: Lifesaver, immune target, and potential remedy for prevention. Med, 2021, 2, 1120-1137.	4.4	4
20	How benign autoimmunity becomes detrimental in type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118 , .	7.1	5
21	Dynamic changes in immune gene co-expression networks predict development of type 1 diabetes. Scientific Reports, $2021,11,22651.$	3.3	3
22	Supplementation with <i>Bifidobacterium longum</i> subspecies <i>infantis</i> EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol. BMJ Open, 2021, 11, e052449.	1.9	15
23	A combined risk score enhances prediction of type 1 diabetes among susceptible children. Nature Medicine, 2020, 26, 1247-1255.	30.7	83
24	Circulating unmethylated CHTOP and INS DNA fragments provide evidence of possible islet cell death in youth with obesity and diabetes. Clinical Epigenetics, 2020, 12, 116.	4.1	17
25	Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. Nature Metabolism, 2020, 2, 1021-1024.	11.9	149
26	Distinct Growth Phases in Early Life Associated With the Risk of Type 1 Diabetes: The TEDDY Study. Diabetes Care, 2020, 43, 556-562.	8.6	28
27	Longitudinal Metabolome-Wide Signals Prior to the Appearance of a First Islet Autoantibody in Children Participating in the TEDDY Study. Diabetes, 2020, 69, 465-476.	0.6	30
28	Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes?. Diabetologia, 2020, 63, 1665-1666.	6.3	7
29	Hierarchical Order of Distinct Autoantibody Spreading and Progression to Type 1 Diabetes in the TEDDY Study. Diabetes Care, 2020, 43, 2066-2073.	8.6	41
30	Soluble ILâ€7 receptor alpha concentration in cord blood is linked to sex and maternal diabetes, but not with subsequent development of type 1 diabetes. European Journal of Immunology, 2020, 50, 903-905.	2.9	1
31	Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA - Journal of the American Medical Association, 2020, 323, 339.	7.4	139
32	Maternal Type 1 Diabetes Reduces Autoantigen-Responsive CD4+ T Cells in Offspring. Diabetes, 2020, 69, 661-669.	0.6	8
33	Birth and coming of age of islet autoantibodies. Clinical and Experimental Immunology, 2019, 198, 294-305.	2.6	35
34	Landmark models to define the age-adjusted risk of developing stage $1\ \rm type\ 1$ diabetes across childhood and adolescence. BMC Medicine, 2019, 17, 125.	5.5	10
35	Age, HLA, and Sex Define a Marked Risk of Organ-Specific Autoimmunity in First-Degree Relatives of Patients With Type 1 Diabetes. Diabetes Care, 2019, 42, 1684-1691.	8.6	12
36	Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. BMJ Open, 2019, 9, e028578.	1.9	62

3

#	Article	IF	CITATIONS
37	Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trialsâ€"GPPADâ€02 study design and first results. Pediatric Diabetes, 2019, 20, 720-727.	2.9	31
38	Gene Expression-Based Identification of Antigen-Responsive CD8+ T Cells on a Single-Cell Level. Frontiers in Immunology, 2019, 10, 2568.	4.8	25
39	Genetic Contribution to the Divergence in Type 1 Diabetes Risk Between Children From the General Population and Children From Affected Families. Diabetes, 2019, 68, 847-857.	0.6	22
40	Common patterns of gene regulation associated with Cesarean section and the development of islet autoimmunity – indications of immune cell activation. Scientific Reports, 2019, 9, 6250.	3.3	4
41	Predicting Islet Cell Autoimmunity and Type 1 Diabetes: An 8-Year TEDDY Study Progress Report. Diabetes Care, 2019, 42, 1051-1060.	8.6	75
42	Inducible IL-7 Hyperexpression Influences Lymphocyte Homeostasis and Function and Increases Allograft Rejection. Frontiers in Immunology, 2019, 10, 742.	4.8	7
43	Cytoplasmic ends of tetraspanin 7 harbour epitopes recognised by autoantibodies in type 1 diabetes. Diabetologia, 2019, 62, 805-810.	6.3	8
44	Tonic Signaling and Its Effects on Lymphopoiesis of CAR-Armed Hematopoietic Stem and Progenitor Cells. Journal of Immunology, 2019, 202, 1735-1746.	0.8	7
45	Screening for asymptomatic \hat{l}^2 -cell autoimmunity in young children. The Lancet Child and Adolescent Health, 2019, 3, 288-290.	5 . 6	8
46	Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System. Frontiers in Immunology, 2019, 10, 38.	4.8	35
47	Time-Resolved Autoantibody Profiling Facilitates Stratification of Preclinical Type 1 Diabetes in Children. Diabetes, 2019, 68, 119-130.	0.6	28
48	Blood draws up to 3% of blood volume in clinical trials are safe in children. Acta Paediatrica, International Journal of Paediatrics, 2019, 108, 940-944.	1.5	15
49	Association of Dendritic Cell Signatures With Autoimmune Inflammation Revealed by Singleâ€Cell Profiling. Arthritis and Rheumatology, 2019, 71, 817-828.	5. 6	11
50	Progression from islet autoimmunity to clinical type 1 diabetes is influenced by genetic factors: results from the prospective TEDDY study. Journal of Medical Genetics, 2019, 56, 602-605.	3.2	22
51	T-cell receptor-α repertoire of CD8+ T cells following allogeneic stem cell transplantation using next-generation sequencing. Haematologica, 2019, 104, 622-631.	3 . 5	16
52	Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes: Action LADA 12. Diabetologia, 2018, 61, 1644-1649.	6.3	42
53	Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study. Molecular Metabolism, 2018, 9, 168-175.	6.5	12
54	Islet-reactive CD8 $<$ sup $>+sup> T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Science Immunology, 2018, 3, .$	11.9	171

#	Article	IF	Citations
55	Early Infant Diet and Islet Autoimmunity in the TEDDY Study. Diabetes Care, 2018, 41, 522-530.	8.6	48
56	Gian Franco Bottazzo, 1946–2017. Diabetologia, 2018, 61, 3-5.	6.3	2
57	Searching peripheral blood mononuclear cells of children with viral respiratory tract infections preceding islet autoimmunity for viruses by high-throughput sequencing. Acta Diabetologica, 2018, 55, 881-884.	2.5	4
58	Assessment of the T cell receptor repertoire in longâ€ŧerm platelet donors by next generation sequencing. British Journal of Haematology, 2018, 181, 389-391.	2.5	1
59	Plasma 25-Hydroxyvitamin D Concentration and Risk of Islet Autoimmunity. Diabetes, 2018, 67, 146-154.	0.6	72
60	Gestational respiratory infections interacting with offspring HLA and CTLA-4 modifies incident \hat{l}^2 -cell autoantibodies. Journal of Autoimmunity, 2018, 86, 93-103.	6.5	22
61	Systems biology of the IMIDIA biobank from organ donors and pancreatectomised patients defines a novel transcriptomic signature of islets from individuals with type 2 diabetes. Diabetologia, 2018, 61, 641-657.	6.3	131
62	Allele-specific methylation of type 1 diabetes susceptibility genes. Journal of Autoimmunity, 2018, 89, 63-74.	6.5	27
63	GM-CSF producing autoreactive CD4+ T cells in type 1 diabetes. Clinical Immunology, 2018, 188, 23-30.	3.2	18
64	Screening for Type 1 Diabetes Risk in Newborns: The Freder1k Pilot Study in Saxony*. Hormone and Metabolic Research, 2018, 50, 44-49.	1.5	15
65	Immunological biomarkers for the development and progression of type 1 diabetes. Diabetologia, 2018, 61, 2252-2258.	6.3	51
66	CD4+ T cell activation, function, and metabolism are inhibited by low concentrations of DMSO. Journal of Immunological Methods, 2018, 463, 54-60.	1.4	7
67	Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: A prospective study in children. PLoS Medicine, 2018, 15, e1002548.	8.4	101
68	Novel minor HLA DR associated antigens in type 1 diabetes. Clinical Immunology, 2018, 194, 87-91.	3.2	8
69	A peripheral blood transcriptomic signature predicts autoantibody development in infants at risk of type $1\ \text{diabetes}$. JCI Insight, 2018, 3, .	5.0	18
70	A divergent population of autoantigen-responsive CD4 <code>⁺</code> T cells in infants prior to \hat{l}^2 cell autoimmunity. Science Translational Medicine, 2017, 9, .	12.4	67
71	Stepwise reprogramming of liver cells to a pancreas progenitor state by the transcriptional regulator Tgif2. Nature Communications, 2017, 8, 14127.	12.8	41
72	Type 1 diabetes mellitus. Nature Reviews Disease Primers, 2017, 3, 17016.	30.5	790

#	Article	IF	Citations
73	CD8+ T cells specific for the islet autoantigen IGRP are restricted in their T cell receptor chain usage. Scientific Reports, 2017, 7, 44661.	3.3	37
74	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes, 2017, 66, 241-255.	0.6	454
75	Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 11745-11750.	7.1	85
76	Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8 ⁺ cytotoxic T cells. Haematologica, 2017, 102, e460-e464.	3.5	7
77	Joint modeling of longitudinal autoantibody patterns and progression to type 1 diabetes: results from the TEDDY study. Acta Diabetologica, 2017, 54, 1009-1017.	2.5	24
78	Persistence of Pancreatic Insulin mRNA Expression and Proinsulin Protein in Type 1 Diabetes Pancreata. Cell Metabolism, 2017, 26, 568-575.e3.	16.2	77
79	Thymus Growth and Fetal Immune Responses in Diabetic Pregnancies. Hormone and Metabolic Research, 2017, 49, 892-898.	1.5	9
80	Regulatory T cell kinetics following adoptive transfer of expanded allogeneic regulatory T cells into patients with chronic graft-versus host disease. Cytotherapy, 2017, 19, S11.	0.7	0
81	Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity. Diabetologia, 2017, 60, 35-38.	6.3	28
82	Generation of high-avidity, WT1-reactive CD8+ cytotoxic T cell clones with anti-leukemic activity by streptamer technology. Leukemia and Lymphoma, 2017, 58, 1246-1249.	1.3	8
83	T cell receptor repertoires after adoptive transfer of expanded allogeneic regulatory T cells. Clinical and Experimental Immunology, 2017, 187, 316-324.	2.6	24
84	Neurotrophin Receptor p75NTR Regulates Immune Function of Plasmacytoid Dendritic Cells. Frontiers in Immunology, 2017, 8, 981.	4.8	14
85	Longitudinal Frequencies of Blood Leukocyte Subpopulations Differ between NOD and NOR Mice but Do Not Predict Diabetes in NOD Mice. Journal of Diabetes Research, 2016, 2016, 1-7.	2.3	5
86	Incomplete immune response to coxsackie B viruses associates with early autoimmunity against insulin. Scientific Reports, 2016, 6, 32899.	3.3	35
87	Tetraspanin 7 autoantibodies in type 1 diabetes. Diabetologia, 2016, 59, 1973-1976.	6.3	33
88	Primary prevention of beta-cell autoimmunity and type 1 diabetes $\hat{a} \in \text{``The Global Platform for the}$ Prevention of Autoimmune Diabetes (GPPAD) perspectives. Molecular Metabolism, 2016, 5, 255-262.	6.5	54
89	Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open, 2016, 6, e011144.	1.9	89
90	Macroporous biohybrid cryogels for co-housing pancreatic islets with mesenchymal stromal cells. Acta Biomaterialia, 2016, 44, 178-187.	8.3	41

#	Article	IF	Citations
91	3 Screen ELISA for High-Throughput Detection of Beta Cell Autoantibodies in Capillary Blood. Diabetes Technology and Therapeutics, 2016, 18, 687-693.	4.4	27
92	3 Screen islet cell autoantibody ELISA: A sensitive and specific ELISA for the combined measurement of autoantibodies to GAD65, to IA-2 and to ZnT8. Clinica Chimica Acta, 2016, 462, 60-64.	1.1	25
93	A novel approach for the analysis of longitudinal profiles reveals delayed progression to type 1 diabetes in a subgroup of multiple-islet-autoantibody-positive children. Diabetologia, 2016, 59, $2172-2180$.	6.3	38
94	Type 1 Diabetes Prevention: A Goal Dependent on Accepting a Diagnosis of an Asymptomatic Disease. Diabetes, 2016, 65, 3233-3239.	0.6	20
95	Abundant cytomegalovirus (CMV) reactive clonotypes in the CD8+ T cell receptor alpha repertoire following allogeneic transplantation. Clinical and Experimental Immunology, 2016, 184, 389-402.	2.6	26
96	Reversion of \hat{I}^2 -Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study. Diabetes Care, 2016, 39, 1535-1542.	8.6	56
97	Validation of a rapid type 1 diabetes autoantibody screening assay for community-based screening of organ donors to identify subjects at increased risk for the disease. Clinical and Experimental Immunology, 2016, 185, 33-41.	2.6	38
98	Effects of Gluten Intake on Risk of Celiac Disease: A Case-Control Study on a Swedish Birth Cohort. Clinical Gastroenterology and Hepatology, 2016, 14, 403-409.e3.	4.4	102
99	Isolation of human monoclonal autoantibodies derived from pancreatic lymph node and peripheral blood B cells of islet autoantibody-positive patients. Diabetologia, 2016, 59, 294-298.	6.3	4
100	ROR1 Specific T Cell Clones from Healthy Individuals Show Common T Cell Receptor Motifs. Blood, 2016, 128, 3364-3364.	1.4	0
101	Predicting Type 1 Diabetes Using Biomarkers. Diabetes Care, 2015, 38, 989-996.	8.6	136
102	The Relative Merits of Cord Blood as a Cell Source for Autologous T Regulatory Cell Therapy in Type 1 Diabetes. Hormone and Metabolic Research, 2015, 47, 48-55.	1.5	7
103	The 6Âyear incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia, 2015, 58, 980-987.	6.3	313
104	Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). Diabetes Care, 2015, 38, 808-813.	8.6	135
105	High Diversity in the TCR Repertoire of GAD65 Autoantigen-Specific Human CD4+ T Cells. Journal of Immunology, 2015, 194, 2531-2538.	0.8	51
106	Progression from single to multiple islet autoantibodies often occurs soon after seroconversion: implications for early screening. Diabetologia, 2015, 58, 411-413.	6.3	29
107	Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. Cytotherapy, 2015, 17, 473-486.	0.7	149
108	Comparison of the purification of biologically active IL-7 cytokine expressed in Escherichia coli and Pichia pastoris. Protein Expression and Purification, 2015, 110, 65-71.	1.3	5

#	Article	IF	CITATIONS
109	Creating a "Transcampus―in Diabetes Research Between King's College London and the Technische Universit¤Dresden: Update on Islet Biology and Transplantation. Hormone and Metabolic Research, 2015, 47, 1-3.	1.5	12
110	Effects of High-Dose Oral Insulin on Immune Responses in Children at High Risk for Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2015, 313, 1541.	7.4	174
111	Widespread seasonal gene expression reveals annual differences in human immunity and physiology. Nature Communications, 2015, 6, 7000.	12.8	367
112	Vagaries of the ELISpot assay: Specific detection of antigen responsive cells requires purified CD8+ T cells and MHC class I expressing antigen presenting cell lines. Clinical Immunology, 2015, 157, 216-225.	3.2	17
113	Compromised immune response in infants at risk for type 1 diabetes born by Caesarean Section. Clinical Immunology, 2015, 160, 282-285.	3.2	12
114	Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes. Diabetologia, 2015, 58, 2317-2323.	6.3	71
115	Relationships between major epitopes of the IA-2 autoantigen in Type 1 diabetes: Implications for determinant spreading. Clinical Immunology, 2015, 160, 226-236.	3.2	12
116	GAD Autoantibody Affinity in Adult Patients With Latent Autoimmune Diabetes, the Study Participants of a GAD65 Vaccination Trial. Diabetes Care, 2014, 37, 1675-1680.	8.6	39
117	Timing of Gluten Introduction and Islet Autoimmunity in Young Children: Updated Results From the BABYDIET Study. Diabetes Care, 2014, 37, e194-e195.	8.6	50
118	IGRP and insulin vaccination induce CD8+ T cell-mediated autoimmune diabetes in the RIP-CD80GP mouse. Clinical and Experimental Immunology, 2014, 176, 199-206.	2.6	3
119	Biomarker discovery study design for type 1 diabetes in The Environmental Determinants of Diabetes in the Young (TEDDY) study. Diabetes/Metabolism Research and Reviews, 2014, 30, 424-434.	4.0	44
120	Feature ranking of type 1 diabetes susceptibility genes improves prediction of type 1 diabetes. Diabetologia, 2014, 57, 2521-2529.	6.3	112
121	Single Molecule Detection of Insulin Autoantibodies in Type 1 Diabetes. Biophysical Journal, 2014, 106, 416a.	0.5	0
122	A strategy to find gene combinations that identify children who progress rapidly to type 1 diabetes after islet autoantibody seroconversion. Acta Diabetologica, 2014, 51, 403-411.	2.5	20
123	Mesenchymal stromal cells improve transplanted islet survival and islet function in a syngeneic mouse model. Diabetologia, 2014, 57, 522-531.	6.3	80
124	Neonatal and infant beta cell hormone concentrations in relation to type 1 diabetes risk. Pediatric Diabetes, 2014, 15, 528-533.	2.9	4
125	Compromised Gut Microbiota Networks in Children With Anti-Islet Cell Autoimmunity. Diabetes, 2014, 63, 2006-2014.	0.6	154
126	A Type I Interferon Transcriptional Signature Precedes Autoimmunity in Children Genetically at Risk for Type 1 Diabetes. Diabetes, 2014, 63, 2538-2550.	0.6	261

#	Article	IF	CITATIONS
127	Interleukin-7 and Type 1 Diabetes. Current Diabetes Reports, 2014, 14, 518.	4.2	20
128	Children followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease. Pediatric Diabetes, 2014, 15, 118-126.	2.9	73
129	Soluble interleukin-2 receptor alpha in preclinical type 1 diabetes. Acta Diabetologica, 2014, 51, 517-518.	2.5	4
130	Risk of Pediatric Celiac Disease According to HLA Haplotype and Country. New England Journal of Medicine, 2014, 371, 42-49.	27.0	270
131	Next-generation sequencing for viruses in children with rapid-onset type 1 diabetes. Diabetologia, 2013, 56, 1705-1711.	6.3	34
132	Concentration and Activity of the Soluble Form of the Interleukin-7 Receptor in Type 1 Diabetes Identifies an Interplay Between Hyperglycemia and Immune Function. Diabetes, 2013, 62, 2500-2508.	0.6	50
133	Transplantation of human islets without immunosuppression. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19054-19058.	7.1	261
134	Measuring T cell receptor and T cell gene expression diversity in antigen-responsive human CD4+ T cells. Journal of Immunological Methods, 2013, 400-401, 13-22.	1.4	24
135	A genomic toolkit to investigate kinesin and myosin motor function in cells. Nature Cell Biology, 2013, 15, 325-334.	10.3	104
136	Targeting innate immunity in type 1 diabetes: strike one. Lancet, The, 2013, 381, 1880-1881.	13.7	1
137	Activation of Islet Autoreactive NaÃ ⁻ ve T Cells in Infants Is Influenced by Homeostatic Mechanisms and Antigen-Presenting Capacity. Diabetes, 2013, 62, 2059-2066.	0.6	34
138	Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children. JAMA - Journal of the American Medical Association, 2013, 309, 2473.	7.4	914
139	Use of dietary supplements in pregnant women in relation to sociodemographic factors $\hat{a} \in \mathbb{C}$ a report from The Environmental Determinants of Diabetes in the Young (TEDDY) study. Public Health Nutrition, 2013, 16, 1390-1402.	2.2	44
140	Alloantibody and Autoantibody Monitoring Predicts Islet Transplantation Outcome in Human Type 1 Diabetes. Diabetes, 2013, 62, 1656-1664.	0.6	105
141	Pretransplantation GAD-Autoantibody Status to Guide Prophylactic Antibody Induction Therapy in Simultaneous Pancreas and Kidney Transplantation. Transplantation, 2013, 96, 745-752.	1.0	11
142	Immunotherapy in Type 1 Diabetes: A Shorter but More Winding Road?. Diabetes, 2012, 61, 2214-2215.	0.6	8
143	IL-7 Abrogates Suppressive Activity of Human CD4+CD25+FOXP3+ Regulatory T Cells and Allows Expansion of Alloreactive and Autoreactive T Cells. Journal of Immunology, 2012, 189, 5649-5658.	0.8	79
144	IA-2 autoantibody affinity in children at risk for type 1 diabetes. Clinical Immunology, 2012, 145, 224-229.	3.2	16

#	Article	IF	Citations
145	Differences in recruitment and early retention among ethnic minority participants in a large pediatric cohort: The TEDDY Study. Contemporary Clinical Trials, 2012, 33, 633-640.	1.8	39
146	A strategy for combining minor genetic susceptibility genes to improve prediction of disease in type 1 diabetes. Genes and Immunity, 2012, 13, 549-555.	4.1	63
147	Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia, 2012, 55, 1937-1943.	6.3	209
148	Genetic association of zinc transporter 8 (ZnT8) autoantibodies in type 1 diabetes cases. Diabetologia, 2012, 55, 1978-1984.	6.3	39
149	The effect of gestation and fetal mismatching on the development of autoimmune diabetes in non-obese diabetic mice. Clinical and Experimental Immunology, 2012, 168, 274-278.	2.6	0
150	Prospective evaluation of risk factors for the development of islet autoimmunity and type 1 diabetes during puberty - TEENDIAB: study design. Pediatric Diabetes, 2012, 13, 419-424.	2.9	30
151	Beta-Cell Autoimmunity. Methods in Molecular Biology, 2012, 933, 265-274.	0.9	4
152	CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. Journal of Clinical Investigation, 2012, 122, 3647-3651.	8.2	129
153	Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. Journal of Autoimmunity, 2011, 37, 3-7.	6.5	65
154	Insulin autoantibodies with high affinity to the bovine milk protein alpha casein. Clinical and Experimental Immunology, 2011, 164, 42-49.	2.6	7
155	Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. Diabetologia, 2011, 54, 433-439.	6.3	34
156	Anti-CCL3 autoantibodies are not markers of type 1 diabetes when measured by a commercial ELISA method. Diabetologia, 2011, 54, 699-700.	6.3	2
157	The Use of Biomaterials in Islet Transplantation. Current Diabetes Reports, 2011, 11, 434-444.	4.2	55
158	Cesarean Section and Interferon-Induced Helicase Gene Polymorphisms Combine to Increase Childhood Type 1 Diabetes Risk. Diabetes, 2011, 60, 3300-3306.	0.6	81
159	Expansion of Th17 Cells and Functional Defects in T Regulatory Cells Are Key Features of the Pancreatic Lymph Nodes in Patients With Type 1 Diabetes. Diabetes, 2011, 60, 2903-2913.	0.6	199
160	Primary Dietary Intervention Study to Reduce the Risk of Islet Autoimmunity in Children at Increased Risk for Type 1 Diabetes. Diabetes Care, 2011, 34, 1301-1305.	8.6	192
161	Age- and Islet Autoimmunity–Associated Differences in Amino Acid and Lipid Metabolites in Children at Risk for Type 1 Diabetes. Diabetes, 2011, 60, 2740-2747.	0.6	96
162	An Interferon-Induced Helicase (<i>IFIH1</i>) Gene Polymorphism Associates With Different Rates of Progression From Autoimmunity to Type 1 Diabetes. Diabetes, 2011, 60, 685-690.	0.6	63

#	Article	IF	Citations
163	Developing and Validating High Sensitivity/Specificity Autoantibody Assays., 2011,, 41-52.		O
164	Mesenchymal Cells Appearing in Pancreatic Tissue Culture Are Bone Marrow-Derived Stem Cells With the Capacity to Improve Transplanted Islet Function Â. Stem Cells, 2010, 28, 140-151.	3.2	70
165	Role of CCL2/MCP-1 in Islet Transplantation. Cell Transplantation, 2010, 19, 1031-1046.	2.5	69
166	Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia, 2010, 53, 2611-2620.	6.3	149
167	The Pancreatic Lymph-nodes of Type 1 Diabetic Patients Contain Epigenetically-imprinted Natural Regulatory T Cells which Lack Suppressive Function. Clinical Immunology, 2010, 135, S21.	3.2	0
168	Proliferation and Lack of Suppressor Capacity of CD4+CD25+FoxP3+ T Regulatory Cells Under the Influence of Interleukin-7. Clinical Immunology, 2010, 135, S123.	3.2	0
169	A simplified method to assess affinity of insulin autoantibodies. Clinical Immunology, 2010, 137, 415-421.	3.2	10
170	Co-Graft of Allogeneic Immune Regulatory Neural Stem Cells (NPC) and Pancreatic Islets Mediates Tolerance, while Inducing NPC-Derived Tumors in Mice. PLoS ONE, 2010, 5, e10357.	2.5	30
171	BMI at Age 8 Years Is Influenced by the Type 2 Diabetes Susceptibility Genes <i>HHEX-IDE</i> and <i>CDKAL1</i> . Diabetes, 2010, 59, 2063-2067.	0.6	11
172	Zinc Transporter 8 Antibodies Complement GAD and IA-2 Antibodies in the Identification and Characterization of Adult-Onset Autoimmune Diabetes. Diabetes Care, 2010, 33, 104-108.	8.6	136
173	No Effect of the $1\hat{l}\pm,25$ -Dihydroxyvitamin D3 on \hat{l}^2 -Cell Residual Function and Insulin Requirement in Adults With New-Onset Type 1 Diabetes. Diabetes Care, 2010, 33, 1443-1448.	8.6	131
174	Harmonization of Glutamic Acid Decarboxylase and Islet Antigen-2 Autoantibody Assays for National Institute of Diabetes and Digestive and Kidney Diseases Consortia. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3360-3367.	3.6	244
175	Impaired insulin turnover in islets from type 2 diabetic patients. Islets, 2010, 2, 30-36.	1.8	20
176	Advances in the Prediction and Natural History of Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 2010, 39, 513-525.	3.2	47
177	German new onset diabetes in the young incident cohort study: DiMelli study design and first-year results. Review of Diabetic Studies, 2010, 7, 202-8.	1.3	23
178	A Report on the International Transglutaminase Autoantibody Workshop for Celiac Disease. American Journal of Gastroenterology, 2009, 104, 154-163.	0.4	116
179	Influence of Early Nutritional Components on the Development of Murine Autoimmune Diabetes. Annals of Nutrition and Metabolism, 2009, 54, 208-217.	1.9	20
180	<i>HHEX-IDE</i> Polymorphism Is Associated with Low Birth Weight in Offspring with a Family History of Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4113-4115.	3.6	11

#	Article	IF	CITATIONS
181	Rapamycin does not adversely affect intrahepatic islet engraftment in mice and improves early islet engraftment in humans. Islets, 2009, 1 , 42-49.	1.8	14
182	An update on preventive and regenerative therapies in diabetes mellitus., 2009, 121, 317-331.		47
183	Azide and Tween-20 reduce binding to autoantibody epitopes of islet antigen-2; implications for assay performance and reproducibility. Journal of Immunological Methods, 2009, 351, 75-79.	1.4	4
184	Disengaging the IL-2 Receptor with Daclizumab Enhances IL-7-Mediated Proliferation of CD4+and CD8+T Cells. American Journal of Transplantation, 2009, 9, 2727-2735.	4.7	24
185	Differentiation, expansion, and homeostasis of autoreactive T cells in type 1 diabetes mellitus. Current Diabetes Reports, 2009, 9, 113-118.	4.2	33
186	Endocrine autoimmunity in families with type 1 diabetes: frequent appearance of thyroid autoimmunity during late childhood and adolescence. Diabetologia, 2009, 52, 185-192.	6.3	18
187	Ghrelin-producing epsilon cells in the developing and adult human pancreas. Diabetologia, 2009, 52, 486-493.	6.3	105
188	Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia, 2009, 52, 1881-1888.	6.3	166
189	Is islet autoimmunity related to insulin sensitivity or body weight in children of parents with type 1 diabetes?. Diabetologia, 2009, 52, 2072-2078.	6.3	23
190	Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applications. Clinical and Experimental Immunology, 2009, 156, 246-253.	2.6	55
191	The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatric Diabetes, 2009, 10, 97-104.	2.9	160
192	Bone marrow as an alternative site for islet transplantation. Blood, 2009, 114, 4566-4574.	1.4	72
193	Autoantibodies to IA-2β improve diabetes risk assessment in high-risk relatives. Diabetologia, 2008, 51, 488-492.	6.3	47
194	Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia, 2008, 51, 846-852.	6.3	239
195	Beta cell chromogranin B is partially segregated in distinct granules and can be released separately from insulin in response to stimulation. Diabetologia, 2008, 51, 997-1007.	6.3	15
196	Maternal type 1 diabetes reduces the risk of islet autoantibodies: relationships with birthweight and maternal HbA1c. Diabetologia, 2008, 51, 1245-1252.	6.3	36
197	Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Current Diabetes Reports, 2008, 8, 87-93.	4.2	71
198	High Levels of Donor CCL2/MCP-1 Predict Graft-Related Complications and Poor Graft Survival After Kidney-Pancreas Transplantation. American Journal of Transplantation, 2008, 8, 1303-1311.	4.7	22

#	Article	IF	Citations
199	Radiobinding assay for detecting autoantibodies to single epitopes. Journal of Immunological Methods, 2008, 336, 127-134.	1.4	6
200	Transplant Estimated Function. Diabetes Care, 2008, 31, 301-305.	8.6	36
201	Mucosal Insulin Vaccination for Type 1 Diabetes Prevention. Experimental and Clinical Endocrinology and Diabetes, 2008, 116, S26-S29.	1.2	9
202	Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4+CD25+FOXP3+ Regulatory T-Cells. Diabetes, 2008, 57, 2341-2347.	0.6	128
203	Exposure to Environmental Factors in Drinking Water: Risk of Islet Autoimmunity and Type 1 Diabetes – The BABYDIAB Study. Hormone and Metabolic Research, 2008, 40, 566-571.	1.5	23
204	Heparin-induced Extracorporal LDL Precipitation (H.E.L.P) in Diabetic Foot Syndrome – Preventive and Regenerative Potential?. Hormone and Metabolic Research, 2008, 40, 487-490.	1.5	28
205	Intrahepatic Islet Transplant in the Mouse: Functional and Morphological Characterization. Cell Transplantation, 2008, 17, 1361-1370.	2.5	33
206	Translating Mucosal Antigen based Prevention of Autoimmune Diabetes to Human. Novartis Foundation Symposium, 2008, 292, 187-201.	1.1	5
207	Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. Journal of Clinical Investigation, 2008, 118, 1806-14.	8.2	159
208	SLC30A8 (ZnT8) Polymorphism is Associated with Young Age at Type 1 Diabetes Onset. Review of Diabetic Studies, 2008, 5, 25-27.	1.3	37
209	GAD Autoantibody Affinity and Epitope Specificity Identify Distinct Immunization Profiles in Children at Risk for Type 1 Diabetes. Diabetes, 2007, 56, 1527-1533.	0.6	81
210	Evidence for In Vivo Primed and Expanded Autoreactive T Cells as a Specific Feature of Patients with Type 1 Diabetes. Journal of Immunology, 2007, 179, 5785-5792.	0.8	116
211	Relevance of Hyperglycemia on the Timing of Functional Loss of Allogeneic Islet Transplants: Implication for Mouse Model. Transplantation, 2007, 83, 167-173.	1.0	29
212	117: Naive and memory T regulatory cells respond to mesenchymal cells regulation. Biology of Blood and Marrow Transplantation, 2007, 13, 45.	2.0	0
213	Chronic myeloproliferative disorders: the bone marrow stromal component is not involved in the malignant clone. Leukemia, 2007, 21, 377-378.	7.2	4
214	Association of immune mediators at diagnosis of TypeÂ1 diabetes with later clinical remission. Diabetic Medicine, 2007, 24, 512-520.	2.3	50
215	Breastfeeding habits in families with TypeÂ1 diabetes. Diabetic Medicine, 2007, 24, 671-676.	2.3	56
216	Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clinical Immunology, 2007, 122, 85-90.	3.2	50

#	Article	IF	Citations
217	Identification of insulin autoantibodies of IgA isotype that preferentially target non-human insulin. Clinical Immunology, 2007, 124, 77-82.	3.2	8
218	Development of autoimmunity to transglutaminase C in children of patients with type 1 diabetes: relationship to islet autoantibodies and infant feeding. Diabetologia, 2007, 50, 390-394.	6.3	42
219	Fetal growth is increased by maternal type 1 diabetes and HLA DR4-related gene interactions. Diabetologia, 2007, 50, 850-858.	6.3	26
220	GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia, 2007, 50, 2052-2060.	6.3	54
221	Induction of Tolerance in Type 1 Diabetes via Both CD4+CD25+ T Regulatory Cells and T Regulatory Type 1 Cells. Diabetes, 2006, 55, 1571-1580.	0.6	151
222	Monoclonal antibody 76F distinguishes IA-2 from IA- $2\hat{l}^2$ and overlaps an autoantibody epitope. Journal of Autoimmunity, 2006, 26, 215-222.	6.5	17
223	Association of interferon \hat{I}^3 and interleukin 10 genotypes and serum levels with partial clinical remission in type 1 diabetes. Clinical and Experimental Immunology, 2006, 145, 480-484.	2.6	31
224	Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives. Diabetologia, 2006, 49, 2969-2976.	6.3	42
225	Rapamycin Induces a Caspase-Independent Cell Death in Human Monocytes. American Journal of Transplantation, 2006, 6, 1331-1341.	4.7	23
226	Predictors of Postpartum Diabetes in Women With Gestational Diabetes Mellitus. Diabetes, 2006, 55, 792-797.	0.6	208
227	Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes, 2006, 55, 40-9.	0.6	72
228	No evidence of diabetes-specific CD38 (ADP ribosil cyclase/cyclic ADP-ribose hydrolase) autoantibodies by liquid-phase immunoprecipitation. Diabetic Medicine, 2005, 22, 1770-1773.	2.3	7
229	IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia, 2005, 48, 703-708.	6.3	83
230	Islet isolation for allotransplantation: variables associated with successful islet yield and graft function. Diabetologia, 2005, 48, 906-912.	6.3	170
231	In insulin-autoantibody-positive children from the general population, antibody affinity identifies those at high and low risk. Diabetologia, 2005, 48, 1830-1832.	6.3	44
232	Predicting type 1 diabetes. Current Diabetes Reports, 2005, 5, 98-103.	4.2	48
233	Neonatal Bacille Calmette-Guerin Vaccination and Type 1 Diabetes. Diabetes Care, 2005, 28, 1204-1206.	8.6	62
234	Natural History of Type 1 Diabetes. Diabetes, 2005, 54, S25-S31.	0.6	223

#	Article	IF	Citations
235	Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood, 2005, 106, 419-427.	1.4	544
236	C-reactive protein concentration is not related to islet autoimmunity status in offspring of parents with type 1 diabetes. Clinical Immunology, 2005, 115, 173-177.	3.2	6
237	Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association. Clinical Immunology, 2005, 117, 31-35.	3.2	23
238	Gluten-Free Diet in Subjects at Risk for Type 1 Diabetes: A Tool for Delaying Progression to Clinical Disease?., 2005, 569, 157-158.		4
239	Autoantibodies. , 2005, , 193-200.		0
240	Pancreatic Â-Cell Function and Immune Responses to Insulin After Administration of Intranasal Insulin to Humans At Risk for Type 1 Diabetes. Diabetes Care, 2004, 27, 2348-2355.	8.6	178
241	Stratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics. Diabetes, 2004, 53, 384-392.	0.6	243
242	IDDM1 and Multiple Family History of Type 1 Diabetes Combine to Identify Neonates at High Risk for Type 1 Diabetes. Diabetes Care, 2004, 27, 2695-2700.	8.6	74
243	Tissue Factor and CCL2/Monocyte Chemoattractant Protein-1 Released by Human Islets Affect Islet Engraftment in Type 1 Diabetic Recipients. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5724-5728.	3.6	60
244	Transmission of Maternal Islet Antibodies and Risk of Autoimmune Diabetes in Offspring of Mothers With Type 1 Diabetes. Diabetes, 2004, 53, 1-4.	0.6	132
245	Up-Regulation of CD1d Expression Restores the Immunoregulatory Function of NKT Cells and Prevents Autoimmune Diabetes in Nonobese Diabetic Mice. Journal of Immunology, 2004, 172, 5908-5916.	0.8	90
246	Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology, 2004, 62, 2092-2094.	1.1	129
247	Immune responses to glutamic acid decarboxylase and insulin in patients with gestational diabetes. Clinical and Experimental Immunology, 2004, 135, 318-321.	2.6	11
248	Maternal immunity to insulin does not affect diabetes risk in progeny of non obese diabetic mice. Clinical and Experimental Immunology, 2004, 136, 56-59.	2.6	17
249	BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with Type 1 diabetes by delaying exposure to gluten. Diabetologia, 2004, 47, 1130-1.	6.3	50
250	Delayed exposure to wheat and barley proteins reduces diabetes incidence in non-obese diabetic mice. Clinical Immunology, 2004, 111, 108-118.	3.2	57
251	Brief Communication: Early Appearance of Islet Autoantibodies Predicts Childhood Type 1 Diabetes in Offspring of Diabetic Parents. Annals of Internal Medicine, 2004, 140, 882.	3.9	132
252	Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. Journal of Clinical Investigation, 2004, 114, 589-597.	8.2	173

#	Article	IF	Citations
253	Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. Journal of Clinical Investigation, 2004, 114, 589-597.	8.2	120
254	IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of Type 1 diabetes and associated autoimmunity. Diabetologia, 2003, 46, 712-720.	6.3	104
255	Fine mapping of diabetes-associated IA-2 specific autoantibodies. Journal of Autoimmunity, 2003, 21, 377-377.	6.5	0
256	Fine mapping of diabetes-associated IA-2 specific autoantibodies. Journal of Autoimmunity, 2003, 21, 377-382.	6.5	16
257	High-resolution snp scan of chromosome 6p21 in pooled samples from patients with complex diseases. Genomics, 2003, 81, 510-518.	2.9	39
258	Characterization of antibody responses to endogenous and exogenous antigen in the nonobese diabetic mouse. Clinical Immunology, 2003, 106, 155-162.	3.2	19
259	Diabetes Antibody Standardization Program: First Assay Proficiency Evaluation. Diabetes, 2003, 52, 1128-1136.	0.6	336
260	Early Infant Feeding and Risk of Developing Type 1 Diabetes–Associated Autoantibodies. JAMA - Journal of the American Medical Association, 2003, 290, 1721.	7.4	432
261	Six Months of Gluten-Free Diet Do Not Influence Autoantibody Titers, but Improve Insulin Secretion in Subjects at High Risk for Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 162-165.	3.6	91
262	Predicting Type 1 Diabetes Using Autoantibodies: The Latest Results from the Diabetes Autoantibody Standardization Program. Diabetes Technology and Therapeutics, 2002, 4, 397-400.	4.4	12
263	Two Distinctly HLA-Associated Contiguous Linear Epitopes Uniquely Expressed Within the Islet Antigen 2 Molecule Are Major Autoantibody Epitopes of the Diabetes-Specific Tyrosine Phosphatase-Like Protein Autoantigens. Journal of Immunology, 2002, 168, 4202-4208.	0.8	28
264	Elimination of Dietary Gluten Does Not Reduce Titers of Type 1 Diabetes-Associated Autoantibodies in High-Risk Subjects. Diabetes Care, 2002, 25, 1111-1116.	8.6	57
265	Succesful transplantation of human islets in recipients bearing a kidney graft. Diabetologia, 2002, 45, 77-84.	6.3	49
266	Reduced IL-4 associated antibody responses to vaccine in early pre-diabetes. Diabetologia, 2002, 45, 677-685.	6.3	16
267	ICA12(SOX13) autoantibodies are unlikely to be a useful marker for pre-clinical Type I diabetes. Diabetologia, 2001, 44, 267-267.	6.3	5
268	T cell responses to type 1 diabetes related peptides sharing homologous regions. Journal of Molecular Medicine, 2001, 79, 213-220.	3.9	10
269	Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: Effect of treatment with interferon. Translational Research, 2001, 137, 38-42.	2.3	48
270	Expression of the Protein Tyrosine Phosphatase-like Protein IA-2 During Pancreatic Islet Development. Journal of Histochemistry and Cytochemistry, 2001, 49, 767-775.	2.5	19

#	Article	IF	Citations
271	Autoantibody Response to Islet Transplantation in Type 1 Diabetes. Diabetes, 2001, 50, 2464-2471.	0.6	120
272	Type 1 Diabetes Mellitus, Celiac Disease and their Association - Lessons from Antibodies. Journal of Pediatric Endocrinology and Metabolism, 2001, 14, 607-10.	0.9	1
273	International Workshop on Lessons From Animal Models for Human Type 1 Diabetes: Identification of Insulin but Not Glutamic Acid Decarboxylase or IA-2 as Specific Autoantigens of Humoral Autoimmunity in Nonobese Diabetic Mice. Diabetes, 2001, 50, 2451-2458.	0.6	108
274	Proinsulin-Specific Autoantibodies Are Relatively Infrequent in Young Offspring With Pre-Type 1 Diabetes. Diabetes Care, 2001, 24, 1843-1844.	8.6	9
275	Risk of Type 1 Diabetes Development in Children With Incidental Hyperglycemia: A multicenter Italian study. Diabetes Care, 2001, 24, 1210-1216.	8.6	34
276	Proposed Guidelines on Screening for Risk of Type 1 Diabetes. Diabetes Care, 2001, 24, 398-398.	8.6	68
277	Prevalence, Characteristics and Diabetes Risk Associated with Transient Maternally Acquired Islet Antibodies and Persistent Islet Antibodies in Offspring of Parents with Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4826-4833.	3.6	44
278	Silent coeliac disease is not a cause of autonomic neuropathy in patients with Type 1 diabetes. Diabetic Medicine, 2001, 18, 686-687.	2.3	2
279	Prevalence, Characteristics and Diabetes Risk Associated with Transient Maternally Acquired Islet Antibodies and Persistent Islet Antibodies in Offspring of Parents with Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4826-4833.	3.6	16
280	No inverse relationship between total IgE levels and islet autoimmunity in children of parents with type 1 diabetes. Diabetes Care, 2000, 23, 1205-1206.	8.6	4
281	Development of celiac disease-associated antibodies in offspring of parents with Type I diabetes. Diabetologia, 2000, 43, 1005-1011.	6.3	71
282	Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. Diabetes, 2000, 49, 218-224.	0.6	88
283	Human Monoclonal Antibodies Isolated from Type I Diabetes Patients Define Multiple Epitopes in the Protein Tyrosine Phosphatase-Like IA-2 Antigen. Journal of Immunology, 2000, 165, 4676-4684.	0.8	29
284	Exposure to exogenous insulin promotes IgG1 and the T-helper 2-associated IgG4 responses to insulin but not to other islet autoantigens. Diabetes, 2000, 49, 918-925.	0.6	41
285	Maturation of the humoral autoimmune response to epitopes of GAD in preclinical childhood type 1 diabetes. Diabetes, 2000, 49, 202-208.	0.6	96
286	Immunoglobulin G Insulin Autoantibodies in BABYDIAB Offspring Appear Postnatally: Sensitive Early Detection Using a Protein A/G-Based Radiobinding Assay ¹ . Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1239-1243.	3.6	38
287	Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study Diabetes, 1999, 48, 460-468.	0.6	588
288	Capillary whole blood measurement of islet autoantibodies. Diabetes Care, 1999, 22, 275-279.	8.6	45

#	Article	IF	Citations
289	Myoclonic encephalopathy and diabetes mellitus in a boy. Developmental Medicine and Child Neurology, 1999, 41, 489-490.	2.1	8
290	Low prevalence of islet autoimmunity in adult diabetes and low predictive value of islet autoantibodies in the general adult population of northern Italy. Diabetologia, 1999, 42, 840-844.	6.3	43
291	Is islet autoimmunity really detectable at birth?. Diabetologia, 1999, 42, 1442-1443.	6.3	3
292	Antibodies to tissue transglutaminase C in Type I diabetes. Diabetologia, 1999, 42, 1195-1198.	6.3	84
293	Comparison of Tissue Transglutaminase-Specific Antibody Assays with Established Antibody Measurements for Coeliac Disease. Journal of Autoimmunity, 1999, 12, 51-56.	6.5	106
294	Cellular and Humoral Immunity against Cow's Milk Proteins in Type 1 Diabetes. Journal of Autoimmunity, 1999, 13, 365-373.	6.5	12
295	Myoclonic encephalopathy and diabetes mellitus in a boy. Developmental Medicine and Child Neurology, 1999, 41, 489-490.	2.1	3
296	Immunoglobulin G Insulin Autoantibodies in BABYDIAB Offspring Appear Postnatally: Sensitive Early Detection Using a Protein A/G-Based Radiobinding Assay. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1239-1243.	3.6	38
297	Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation. Journal of Immunology, 1999, 163, 525-32.	0.8	77
298	Myoclonic encephalopathy and diabetes mellitus in a boy. Developmental Medicine and Child Neurology, 1999, 41, 489-90.	2.1	4
299	Gluten: is it also a determinant of islet autoimmunity?. , 1998, 14, 258-259.		6
300	Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus., 1998, 15, 844-850.		68
301	IA-2 antibodies - a sensitive marker of IDDM with clinical onset in childhood and adolescence. Diabetologia, 1998, 41, 424-429.	6.3	154
302	Comparison of a novel micro-assay for insulin autoantibodies with the conventional radiobinding assay. Diabetologia, 1998, 41, 681-683.	6.3	70
303	Autoimmune responses to the \hat{l}^2 cell autoantigen, insulin, and the INS VNTR-IDDM2 locus. Clinical and Experimental Immunology, 1998, 114, 370-376.	2.6	18
304	Tissue transglutaminase and combined screening for coeliac disease and type 1 diabetesassociated autoantibodies. Lancet, The, 1998, 352, 1192-1193.	13.7	65
305	Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 204-208.	1.9	25
306	Two-Step Islet Autoantibody Screening for Risk Assessment of Type 1 Diabetes in Relatives. Diabetes Care, 1998, 21, 1445-1450.	8.6	36

#	Article	IF	CITATIONS
307	Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus. Diabetic Medicine, 1998, 15, 844-850.	2.3	5
308	IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. Journal of Immunology, 1998, 161, 2648-54.	0.8	48
309	Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. Journal of Immunology, 1998, 161, 6963-9.	0.8	57
310	Evaluation of Islet Cell Antigen (ICA) 512/IA-2 Autoantibody Radioassays Using Overlapping ICA512/IA-2 Constructs ¹ . Journal of Clinical Endocrinology and Metabolism, 1997, 82, 375-380.	3.6	46
311	Prediction of IDDM in the General Population: Strategies Based on Combinations of Autoantibody Markers. Diabetes, 1997, 46, 1701-1710.	0.6	394
312	Low Prevalence of Islet Autoantibodies in Patients With Gestational Diabetes Mellitus. Diabetes Care, 1997, 20, 81-83.	8.6	41
313	Islet Cell Antigens in the Prediction and Prevention of Insulin-dependent Diabetes Mellitus. Annals of Medicine, 1997, 29, 405-412.	3.8	14
314	Lack of Association of DMB Polymorphism with Insulin-Dependent Diabetes. Journal of Autoimmunity, 1997, 10, 395-400.	6.5	5
315	A Novel Micro-assay for Insulin Autoantibodies. Journal of Autoimmunity, 1997, 10, 473-478.	6.5	215
316	Islet autoantibodies and their use in predicting insulin-dependent diabetes. Acta Diabetologica, 1997, 34, 185-193.	2.5	26
317	Evaluation of Islet Cell Antigen (ICA) 512/IA-2 Autoantibody Radioassays Using Overlapping ICA512/IA-2 Constructs. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 375-380.	3.6	32
318	Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes, 1997, 46, 1701-1710.	0.6	152
319	Association of IA-2 autoantibodies with HLA DR4 phenotypes in IDDM. Diabetologia, 1996, 39, 1223-1226.	6.3	84
320	Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. Journal of Immunology, 1996, 157, 2707-11.	0.8	56
321	Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia, 1995, 38, 816-822.	6.3	163
322	HLA-DQ screening for risk assessment of insulin dependent diabetes in northern Italy. Acta Diabetologica, 1995, 32, 137-142.	2.5	3
323	HLA DQA1-DQB1-TAP2 haplotypes in IDDM families: no evidence for an additional contribution to disease risk by the TAP2 locus. Diabetologia, 1995, 38, 968-974.	6.3	13
324	HLA-A associations with IDDM? a case of numbers?. Diabetologia, 1995, 38, 751-752.	6.3	3

#	Article	IF	CITATIONS
325	Disease Sensitivity and Specificity of 52 Assays for Glutamic Acid Decarboxylase Antibodies: The Second International GADAB Workshop. Diabetes, 1995, 44, 636-640.	0.6	139
326	Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies. The Second International GADAB Workshop. Diabetes, 1995, 44, 636-640.	0.6	43
327	HLA DQA1-DQB1-TAP2 haplotypes in IDDM families: no evidence for an additional contribution to disease risk by the TAP2 locus. Diabetologia, 1995, 38, 968-974.	6.3	0
328	Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. Journal of Immunology, 1995, 155, 5419-26.	0.8	137
329	Lack of Immunohistological Changes in the Islets of Nondiabetic, Autoimmune, Polyendocrine Patients With Â-Selective GAD-Specific Islet Cell Antibodies. Diabetes, 1994, 43, 851-856.	0.6	42
330	Combined Analysis of Autoantibodies Improves Prediction of IDDM in Islet Cell Antibody-Positive Relatives. Diabetes, 1994, 43, 1304-1310.	0.6	360
331	High Level of Concordance Between Assays for Glutamic Acid Decarboxylase Antibodies: The First International Glutamic Acid Decarboxylase Antibody Workshop. Diabetes, 1994, 43, 1005-1009.	0.6	90
332	Antibodies to Islet 37k Antigen, But Not to Glutamate Decarboxylase, Discriminate Rapid Progression to IDDM in Endocrine Autoimmunity. Diabetes, 1994, 43, 1254-1259.	0.6	122
333	Low interleukin-2 receptor levels in serum of patients with insulin-dependent diabetes. The Clinical Investigator, 1994, 72, 494-8.	0.6	4
334	Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease. Diabetologia, 1994, 37, 365-371.	6.3	28
335	Autoantibodies to glutamic acid decarboxylase in palatal myoclonus and epilepsy. Annals of Neurology, 1994, 36, 665-667.	5.3	93
336	Sera from Patients with IDDM and Healthy Individuals have Antibodies to ICA69 on Western Blots but do not Immunoprecipitate Liquid Phase Antigen. Journal of Autoimmunity, 1994, 7, 665-674.	6.5	34
337	Combined analysis of IDDM-related autoantibodies in healthy schoolchildren. Lancet, The, 1994, 344, 756.	13.7	18
338	Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus. Lancet, The, 1994, 344, 266-267.	13.7	5
339	Autoantibodies in insulin-dependent diabetes mellitus. Journal of Endocrinological Investigation, 1994, 17, 521-531.	3.3	6
340	T-cell reactivity to 38 kD insulin-secretory granule protein in patients with recent onset type 1 diabetes. Journal of Endocrinological Investigation, 1994, 17, 559-563.	3.3	2
341	Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes, 1994, 43, 1254-1259.	0.6	36
342	Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes, 1994, 43, 1304-1310.	0.6	109

#	Article	IF	CITATIONS
343	Lack of immunohistological changes in the islets of nondiabetic, autoimmune, polyendocrine patients with beta-selective GAD-specific islet cell antibodies. Diabetes, 1994, 43, 851-856.	0.6	14
344	High level of concordance between assays for glutamic acid decarboxylase antibodies. The First International Glutamic Acid Decarboxylase Antibody Workshop. Diabetes, 1994, 43, 1005-1009.	0.6	28
345	Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease. Diabetologia, 1994, 37, 365-371.	6.3	3
346	Can Islet Cell Antibodies Predict IDDM in the General Population?. Diabetes Care, 1993, 16, 45-50.	8.6	79
347	Can We Really Predict IDDM?. Diabetes, 1993, 42, 213-220.	0.6	113
348	Can we really predict IDDM?. Diabetes, 1993, 42, 213-220.	0.6	42
349	Distinct cytoplasmic islet cell antibodies with different risks for Type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1992, 35, 385-388.	6.3	133
350	Early T-cell defects in pre-type 1 diabetes. Acta Diabetologica, 1992, 28, 189-192.	2.5	9
351	Idiopathic dilated cardiomyopathy: lack of association between circulating organâ€specific cardiac antibodies and HLAâ€DR antigens. Tissue Antigens, 1992, 39, 236-240.	1.0	26
352	Organ-specific cardiac antibodies: serological markers for systemic hypertension in autoimmune polyendocrinopathy. Lancet, The, 1991, 337, 1111-1115.	13.7	25
353	Progression to Type I Diabetess in Autoimmune Endocrine Patients With Islet Cell Antibodies. Diabetes, 1991, 40, 977-984.	0.6	48
354	Novel Considerations on the Antibody/Autoantigen System in Type I (insulin-dependent) Diabetes Mellitus. Annals of Medicine, 1991, 23, 453-461.	3.8	27
355	Progression to type I diabetes in autoimmune endocrine patients with islet cell antibodies. Diabetes, 1991, 40, 977-984.	0.6	17
356	The third international workshop on the standardisation of insulin autoantibody measurement. Diabetologia, 1990, 33, 60-61.	6.3	32
357	Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays. Diabetologia, 1990, 33, 731-736.	6.3	70
358	Inappropriate major histocompatibility complex expression on cardiac tissue in dilated cardiomyopathy. Relevance for autoimmunity?. Journal of Autoimmunity, 1990, 3, 187-200.	6.5	82
359	Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet, The, 1990, 335, 147-149.	13.7	382
360	Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. Journal of the American College of Cardiology, 1990, 15, 1527-1534.	2.8	188

#	Article	IF	CITATIONS
361	Comparison of Insulin Autoantibodies in Diabetes-Related and Healthy Populations by Precise Displacement ELISA. Diabetes, 1989, 38, 1275-1281.	0.6	22
362	Systematic Variation and Differences in Insulin-Autoantibody Measurements. Diabetes, 1989, 38, 172-181.	0.6	29
363	Pathogenesis of Type I (insulin-dependent) diabetes: Possible mechanisms of autoimmune damage. British Medical Bulletin, 1989, 45, 37-57.	6.9	15
364	Comparison of insulin autoantibodies in diabetes-related and healthy populations by precise displacement ELISA. Diabetes, 1989, 38, 1275-1281.	0.6	7
365	Systematic variation and differences in insulin-autoantibody measurements. Diabetes, 1989, 38, 172-181.	0.6	19
366	The second international workshop on the standardisation of insulin autoantibody (IAA) measurement. Diabetologia, 1988, 31, 449-450.	6.3	43
367	Immunology and diabetes workshop: Report on the third international (Stage 3) workshop on the standardisation of cytoplasmic islet cell antibodies. Diabetologia, 1988, 31, 451-452.	6.3	71
368	Serum exchange and use of dilutions have improved precision of measurement of islet cell antibodies. Journal of Immunological Methods, 1988, 106, 83-88.	1.4	122
369	Standardization of Acetylcholine Receptor Antibody Measurement. Annals of the New York Academy of Sciences, 1988, 540, 528-529.	3.8	0
370	Comparison and Standardization of Measurement of Anti-Acetylcholine Receptor Antibody between Laboratories. Autoimmunity, 1988, 1, 59-66.	2.6	2
371	SEAPAL quality control analysis of rheumatoid factor measurement in 29 diagnostic laboratories Annals of the Rheumatic Diseases, 1987, 46, 417-420.	0.9	8
372	Immunology and Diabetes Workshops: Report of the Second International Workshop on the Standardisation of Cytoplasmic Islet Cell Antibodies. Diabetologia, 1987, 30, 273-273.	6.3	37
373	First international workshop on the standardisation of insulin autoantibodies. Diabetologia, 1987, 30, 676-677.	6.3	32
374	Western blot profiles, lymph node ultrastructure and viral expression in HIV-infected patients: a correlative study. Clinical and Experimental Immunology, 1987, 68, 465-78.	2.6	23
375	Use of a standard curve improves precision and concordance of antinuclear antibody measurement. Journal of Clinical & Laboratory Immunology, 1987, 22, 197-200.	0.1	9
376	Antinuclear antibody. Journal of Immunological Methods, 1986, 91, 249-255.	1.4	17
377	The willingness to participate in pediatric type 1 diabetes studies. Deutsches A& $\#$ x0308; $\#$ zteblatt International, 0, , .	0.9	0
378	A Novel Type I Interferon Primed Dendritic Cell Subpopulation in TREX1 Mutant Chilblain Lupus Patients. Frontiers in Immunology, 0, 13, .	4.8	2